16LBA VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer
暂无分享,去创建一个
P. Carmeliet | D. Lambrechts | C. Verslype | S. Scherer | P. Delmar | B. Claes | E. Cutsem | I. Buysschaert | D. Foernzler | B. T. Yesilyurt | B. Yesilyurt